Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Safety and Effectiveness of Rivaroxaban Versus Low Molecular Weight Heparin for Treatment of Cancer-Associated Venous Thrombosis: A SEER-Medicare-Linked Data Analysis

Christine G. Kohn, PharmD, Gary H. Lyman, MD MPH, Nicole M. Kuderer, Thomas J. Bunz, PharmD, PhD, Craig I. Coleman, PharmD

Blood (2019) 134 (Supplement_1): 3673.

https://doi.org/10.1182/blood-2019-128581

Published: 2019

Journal Articles

External Validation of a Clinical and Claims-Based Approach for Predicting 90-Day Post-Pulmonary Embolism Outcomes Among US Veterans

Neela K Kumar, MSPH, Erin R Weeda, PharmD, Philip S Wells, MD, Frank Peacock, MD, Gregory J Fermann, MD, Li Wang, MA, PhD MBA, Onur Baser, MS, PhD, Jeff Schein, DrPH, MPH, Crivera Crivera, PharmD, MPH, Craig I Coleman, PharmD, Christine G Kohn, PharmD

Blood (2016) 128 (22): 533.

https://doi.org/10.1182/blood.V128.22.533.533

Published: 2016

Journal Articles

Reduced Costs and Length-of-Stay Associated with Rivaroxaban As Compared to Parenteral Bridging and Warfarin in Pulmonary Embolism Patients Managed in Observation Status

Christine G Kohn, PharmD, Erin R Weeda, PharmD, W Frank Peacock, MD FACEP, Gregory J Fermann, MD, Christopher W. Baugh, MD MBA, Philip S Wells, MD FRCPC, MSc, Veronica Ashton, MPH, Concetta Crivera, PharmD, MPH, Peter Wildgoose, PhD, Jeff Schein, DrPH, MPH, Craig I Coleman, PharmD

Blood (2016) 128 (22): 2337.

https://doi.org/10.1182/blood.V128.22.2337.2337

Published: 2016

Journal Articles

External Validation of Generic and Cancer-Specific Risk Stratification Criteria for Predicting 30-Day Mortality in Patients Presenting with Pulmonary Embolism and Active Cancer

Jonathan T Caranfa, PharmD, Erin R Weeda, PharmD, Craig I Coleman, PharmD, Simon B. Zeichner, D.O., Christine G Kohn, PharmD

Blood (2016) 128 (22): 4730.

https://doi.org/10.1182/blood.V128.22.4730.4730

Published: 2016

Journal Articles

Validation of the Inhospital Mortality for Pulmonary Embolism Using Claims Data (IMPACT) Prediction Rule within an All-Payer Inpatient Administrative Claims Database

Craig I Coleman, PharmD, Christine G Kohn, PharmD, Concetta Crivera, Jeff Schein, W Frank Peacock, MD FACEP

Blood (2015) 126 (23): 747.

https://doi.org/10.1182/blood.V126.23.747.747

Published: 2015

Journal Articles

Does the Timing of Vital Sign Measurements Affect Simplified Pulmonary Embolism Severity Index (sPESI) Risk Determination?

Christine G Kohn, PharmD, Heather Rozjabek, MPH, Gregory J Fermann, MD, W Frank Peacock, MD FACEP, Concetta Crivera, Jeff Schein, Craig I Coleman, PharmD

Blood (2015) 126 (23): 2058.

https://doi.org/10.1182/blood.V126.23.2058.2058

Published: 2015

Journal Articles

Pulmonary Embolism Begets Pulmonary Embolism?: A Meta-Analysis Depicting the Type of Recurrence Following an Index Pulmonary Embolism

Craig I Coleman, PharmD, Christine G Kohn, PharmD, Dhaval Patel, BS

Blood (2014) 124 (21): 4832.

https://doi.org/10.1182/blood.V124.21.4832.4832

Published: 2014

NARROW

Safety and Effectiveness of Rivaroxaban Versus Low Molecular Weight Heparin for Treatment of Cancer-Associated Venous Thrombosis: A SEER-Medicare-Linked Data Analysis

External Validation of a Clinical and Claims-Based Approach for Predicting 90-Day Post-Pulmonary Embolism Outcomes Among US Veterans

Reduced Costs and Length-of-Stay Associated with Rivaroxaban As Compared to Parenteral Bridging and Warfarin in Pulmonary Embolism Patients Managed in Observation Status

External Validation of Generic and Cancer-Specific Risk Stratification Criteria for Predicting 30-Day Mortality in Patients Presenting with Pulmonary Embolism and Active Cancer

Validation of the Inhospital Mortality for Pulmonary Embolism Using Claims Data (IMPACT) Prediction Rule within an All-Payer Inpatient Administrative Claims Database

Does the Timing of Vital Sign Measurements Affect Simplified Pulmonary Embolism Severity Index (sPESI) Risk Determination?

Pulmonary Embolism Begets Pulmonary Embolism?: A Meta-Analysis Depicting the Type of Recurrence Following an Index Pulmonary Embolism

Email alerts

ASH Publications

American Society of Hematology

Safety and Effectiveness of Rivaroxaban Versus Low Molecular Weight Heparin for Treatment of Cancer-Associated Venous Thrombosis: A SEER-Medicare-Linked Data Analysis

External Validation of a Clinical and Claims-Based Approach for Predicting 90-Day Post-Pulmonary Embolism Outcomes Among US Veterans

Reduced Costs and Length-of-Stay Associated with Rivaroxaban As Compared to Parenteral Bridging and Warfarin in Pulmonary Embolism Patients Managed in Observation Status

External Validation of Generic and Cancer-Specific Risk Stratification Criteria for Predicting 30-Day Mortality in Patients Presenting with Pulmonary Embolism and Active Cancer

Validation of the Inhospital Mortality for Pulmonary Embolism Using Claims Data (IMPACT) Prediction Rule within an All-Payer Inpatient Administrative Claims Database

Does the Timing of Vital Sign Measurements Affect Simplified Pulmonary Embolism Severity Index (sPESI) Risk Determination?

Pulmonary Embolism Begets Pulmonary Embolism?: A Meta-Analysis Depicting the Type of Recurrence Following an Index Pulmonary Embolism

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only